American Renal Associates Holdings, Inc (NYSE:ARA) – SunTrust Banks issued their Q1 2019 earnings estimates for American Renal Associates Holdings in a report released on Thursday. SunTrust Banks analyst D. Macdonald expects that the company will earn $0.15 per share for the quarter. SunTrust Banks also issued estimates for American Renal Associates Holdings’ Q2 2019 earnings at $0.21 EPS.

Separately, Zacks Investment Research raised shares of American Renal Associates Holdings from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a report on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $22.33.

COPYRIGHT VIOLATION NOTICE: “Brokers Offer Predictions for American Renal Associates Holdings, Inc’s Q1 2019 Earnings (ARA)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/19/brokers-offer-predictions-for-american-renal-associates-holdings-incs-q1-2019-earnings-ara.html.

American Renal Associates Holdings (ARA) traded down 2.74% during mid-day trading on Monday, reaching $14.56. 29,043 shares of the company’s stock traded hands. The stock’s market capitalization is $455.51 million. American Renal Associates Holdings has a 52 week low of $14.23 and a 52 week high of $24.94. The stock’s 50 day moving average is $14.85 and its 200-day moving average is $15.88.

American Renal Associates Holdings (NYSE:ARA) last released its earnings results on Tuesday, August 8th. The company reported $0.16 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.04. The company had revenue of $185.99 million for the quarter, compared to the consensus estimate of $188.23 million. American Renal Associates Holdings had a negative net margin of 1.54% and a positive return on equity of 18.25%. The company’s quarterly revenue was up .2% on a year-over-year basis.

Hedge funds have recently added to or reduced their stakes in the business. Taylor Cottrill Erickson & Associates Inc. purchased a new position in shares of American Renal Associates Holdings during the second quarter worth approximately $12,137,000. FMR LLC grew its position in shares of American Renal Associates Holdings by 14.3% during the first quarter. FMR LLC now owns 3,989,578 shares of the company’s stock worth $67,344,000 after acquiring an additional 500,624 shares during the last quarter. Van Berkom & Associates Inc. purchased a new position in shares of American Renal Associates Holdings during the second quarter worth approximately $6,886,000. AMI Asset Management Corp grew its position in shares of American Renal Associates Holdings by 26.2% during the second quarter. AMI Asset Management Corp now owns 564,753 shares of the company’s stock worth $10,476,000 after acquiring an additional 117,422 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of American Renal Associates Holdings by 11.6% during the first quarter. Vanguard Group Inc. now owns 928,768 shares of the company’s stock worth $15,678,000 after acquiring an additional 96,196 shares during the last quarter. 89.92% of the stock is currently owned by institutional investors.

American Renal Associates Holdings Company Profile

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

Earnings History and Estimates for American Renal Associates Holdings (NYSE:ARA)

Receive News & Stock Ratings for American Renal Associates Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc and related stocks with our FREE daily email newsletter.